The article discusses various reports published within the issue, including one by Chantal Mathieu and Saskia Robberecht on the addition of insulin to a range of therapies for treatment of type 2 diabetes mellitus, and another by Stephan Schreiber on the overall clinical setting of insulin glargine in treatment of type 2 diabetes mellitus.